Our analysis revealed that the frequency of ABI3 alterations varied across pan-cancer, with the highest prevalence of copy number alterations observed in BRCA, MESO, and UCS, where the majority of cases were amplifications (Figure 5A). This evidence concerns the gene ABI3 and cancer.